美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Generate Biomedicines

12.61

+0.11000.88%

盤後：12.610.00000.00%17:23 EDT

成交量：29.14萬

成交額：367.22萬

市值：16.07億

市盈率：-6.44

高：12.88

開：12.60

低：12.35

收：12.50

52周最高：15.32

52周最低：11.00

股本：1.27億

流通股本：2,500.00萬

量比：0.85

換手率：1.17%

股息：- -

股息率：- -

每股收益(TTM):-1.9580

每股收益(LYR):-4.9816

淨資產收益率：-81.72%

總資產收益率：-34.63%

市淨率：-2.61

市盈率(LYR):-2.53

資料載入中...

總覽公司新聞資訊公告

BUZZ-摩根士丹利看好 Generate Biomedicines，稱主要哮喘藥物實力強勁

摩根士丹利首予Generate Biomedicines增持評級目標價20美元

Piper Sandler首予Generate Biomedicines增持評級目標價24美元

異動解讀 | 市場波動引發投資者謹慎，Generate Biomedicines盤中大跌9.38%

藥物開發商 Generate Biomedicines 首次登陸納斯達克表現疲軟，股價下跌

BUZZ-旗艦企業 Generate Biomedicines 首次公開募股 4 億美元后將在納斯達克上市

AI製藥企業Generate Biomedicines(GENB.US)IPO定價16美元/股今晚登陸納斯達克

智通财经网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/GENB/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GENB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","market":"US","secType":"STK","nameCN":"Generate Biomedicines","latestPrice":12.61,"timestamp":1776369600000,"preClose":12.5,"halted":0,"volume":291397,"hourTrading":{"tag":"盘后","latestPrice":12.61,"preClose":12.61,"latestTime":"17:23 EDT","volume":610,"amount":7691.9,"timestamp":1776374616462,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.008799999999999954,"floatShares":25000000,"shares":127450200,"eps":-1.958,"marketStatus":"未開盤","change":0.11,"latestTime":"04-16 16:00:00 EDT","open":12.6,"high":12.88,"low":12.35,"amount":3672204.808996,"amplitude":0.0424,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.958,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1776412800000},"marketStatusCode":0,"adr":0,"listingDate":1772168400000,"exchange":"NASDAQ","adjPreClose":12.5,"preHourTrading":{"tag":"盘前","latestPrice":12.51,"preClose":12.5,"latestTime":"09:28 EDT","volume":190,"amount":2424.00993,"timestamp":1776346119624,"change":0.01,"changeRate":0.0008,"amplitude":0.036},"postHourTrading":{"tag":"盘后","latestPrice":12.61,"preClose":12.61,"latestTime":"17:23 EDT","volume":610,"amount":7691.9,"timestamp":1776374616462,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.853717},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","floatShares":25000000,"roa":"-34.63%","roe":"-81.72%","lyrEps":-4.981642,"volumeRatio":0.853717,"shares":127450200,"dividePrice":0,"high":12.88,"amplitude":0.0424,"preClose":12.5,"low":12.35,"week52Low":11,"pbRate":"-2.61","psRate":"50.39","week52High":15.32,"institutionHeld":0,"latestPrice":12.61,"eps":-1.958,"divideRate":0,"volume":291397,"delay":0,"ttmEps":-1.958,"open":12.6,"prevYearClose":16,"prevWeekClose":11.41,"prevMonthClose":12.5,"prevQuarterClose":12.5,"fiveDayClose":11.53,"twentyDayClose":11.81,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GENB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GENB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GENB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1776139200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GENB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GENB","date":"2026-04-15","current":-6.440245,"percent":0.15625,"low":-10.037721,"twenty":-8.048998,"median":-7.660036,"eighty":-7.414112,"high":-7.032678,"avg":-7.763645,"sd":0.548051,"marketCap":1642833090},"quantilePoints":[{"date":"2026-02-27","current":-10.037721,"twenty":-10.037721,"median":-10.037721,"eighty":-10.037721,"marketCap":2039203216},{"date":"2026-03-06","current":-7.810602,"twenty":-7.936073,"median":-7.722772,"eighty":-7.484376,"marketCap":1586755002},{"date":"2026-03-13","current":-8.331309,"twenty":-7.979988,"median":-7.660036,"eighty":-7.484376,"marketCap":1692538669},{"date":"2026-03-20","current":-7.710225,"twenty":-7.979988,"median":-7.68513,"eighty":-7.484376,"marketCap":1566362970},{"date":"2026-03-27","current":-8.061545,"twenty":-7.979988,"median":-7.697677,"eighty":-7.484376,"marketCap":1637735082},{"date":"2026-04-02","current":-8.350129,"twenty":-7.996299,"median":-7.697677,"eighty":-7.419131,"marketCap":1696362175},{"date":"2026-04-10","current":-7.233433,"twenty":-7.996299,"median":-7.647489,"eighty":-7.419131,"marketCap":1469500817},{"date":"2026-04-15","current":-8.086639,"twenty":-8.048998,"median":-7.660036,"eighty":-7.414112,"marketCap":1642833090}],"updateTime":1776397228341},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GENB\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622006871","title":"BUZZ-摩根士丹利看好 Generate Biomedicines，稱主要哮喘藥物實力強勁","url":"https://stock-news.laohu8.com/highlight/detail?id=2622006871","media":"路透中文","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622006871?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 01:52","pubTimestamp":1774461151,"startTime":"0","endTime":"0","summary":"3月25日 - ** 随着研究静默期的结束，摩根士丹利给予药物开发商 Generate Biomedicines GENB.O \"增持 \"评级** 该公司上月底在纳斯达克上市后，在开盘时获得了近19.1亿美元的估值 。** 券商称，\"我们认为 GENB 的主要资产 GB-0895 与生产重磅药物的商业基准相比，具有同类最佳的潜力\"。** GB-0895 是 GENB 公司治疗严重哮喘的主导产品，目前正在进行后期试验。** 高盛、摩根士丹利、派珀桑德勒、古根海姆证券和坎特是 GENB 公司此次发行的承销商。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nL4T40D1SM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPR","BK4127","GENB","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170560375","title":"摩根士丹利首予Generate Biomedicines增持評級 目標價20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1170560375","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170560375?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 20:45","pubTimestamp":1774356311,"startTime":"0","endTime":"0","summary":"摩根士丹利宣布，首次覆盖生物医药公司Generate Biomedicines，并给予“增持”评级。该机构同时设定了20美元的目标股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184653688","title":"Piper Sandler首予Generate Biomedicines增持評級 目標價24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184653688","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184653688?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 15:44","pubTimestamp":1774338251,"startTime":"0","endTime":"0","summary":"Piper Sandler近日宣布，正式启动对生物医药公司Generate Biomedicines的研究覆盖，并给予其\"增持\"评级。该机构同时设定了24美元的目标股价，显示出对该公司未来增长潜力的积极预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165464916","title":"異動解讀 | 市場波動引發投資者謹慎，Generate Biomedicines盤中大跌9.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=1165464916","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165464916?lang=zh_tw&edition=fundamental","pubTime":"2026-02-28 02:10","pubTimestamp":1772215808,"startTime":"0","endTime":"0","summary":"Generate Biomedicines（GENB）今日盘中股价大跌9.38%，引起了市场的广泛关注。消息面上，由于挥之不去的市场波动使投资者对新上市企业保持谨慎，导致该股在首次上市时股价承压。根据相关报道，市场整体波动性使得投资者风险偏好降低，对新上市的股票采取更为保守的态度，从而影响了Generate Biomedicines的股价表现。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614667738","title":"藥物開發商 Generate Biomedicines 首次登陸納斯達克表現疲軟，股價下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2614667738","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614667738?lang=zh_tw&edition=fundamental","pubTime":"2026-02-28 02:09","pubTimestamp":1772215781,"startTime":"0","endTime":"0","summary":"人工智能、资本和大股东Generate Biomedicines 公司自称是将人工智能应用于生物技术和药物设计的先驱，该公司计划将首次公开募股的大部分收益用于完成其领先的哮喘药物的两项三期试验。\" Generate Biomedicines 的早期成果包括一种 新冠 抗体，该抗体显示出广泛的变异抗性活性，但鉴于 新冠 预防性疗法的市场条件不断变化，该公司已搁置了该抗体的开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL4S3ZN1SK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVDS","ANV","LU0210528500.USD","LU2931357623.SGD","SNVD.UK","GENB","LU2063271972.USD","NVDY","AMGN","LU1815333072.USD","AKTS","MRNA","HK0000306685.HKD","LU0557290698.USD","LU1989764748.USD","NVD","NVDG","BK4566","NVD2.UK","LU0719512351.SGD","BK4614","3NVD.UK","LU2430703095.HKD","NVDB","SG9999014914.USD","NVDD","NVII","NVDL","DIPS","LU0494093205.USD","IE0034235303.USD","BK4588","NVDW","NVDX","LU2471134952.CNY","IE00B5949003.HKD","NVDQ","2NVD.UK","NVIW.SI","NVD3.UK","LU2242650005.HKD","MRNY","NVDA","NVDU","LU2023251221.USD","LU0053666078.USD","HK0000914686.HKD","MRNX","IE00BFSS7M15.SGD","NVDS.UK"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2614855369","title":"BUZZ-旗艦企業 Generate Biomedicines 首次公開募股 4 億美元后將在納斯達克上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2614855369","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614855369?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 20:48","pubTimestamp":1772196508,"startTime":"0","endTime":"0","summary":"2月27日 - ** 药物开发商 Generate Biomedicines GENB.O由风险投资公司 Flagship Pioneering 支持，将于周五晚些时候在纳斯达克上市交易，股票代码为 \"GENB\"。*  * GENB在首次公开募股中以每股16美元的价格出售了2500万股股票，募集资金4亿美元，而市场定价区间为每股15美元至17美元。** Generate于2018年由Flagship创立，其药物管线主要集中在免疫学和肿瘤学领域。** Generate公司治疗重症哮喘的主要候选产品GB-0895正在进行后期试验，预计将于2028年上半年全部入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL4S3ZN15R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225283273.USD","LU2237443978.SGD","LU0742534661.SGD","LU1244550494.USD","LU0345770993.USD","LU0882574139.USD","GENB","BK4127","LU1720051108.HKD","BK4585","LU2471134523.USD","LU0106831901.USD","GSX","LU0795875086.SGD","LU0557290698.USD","LU2028103732.USD","LU1791710400.SGD","LU2237443549.SGD","LU2111349929.HKD","LU0251131958.USD","LU2133065610.SGD","LU1791807156.HKD","LU1732799900.SGD","LU1894683264.USD","LU1720051017.SGD","LU1989772923.USD","LU0006306889.USD","LU2471134879.HKD","BK4504","LU2357305700.SGD","LU1989772840.SGD","LU0158827781.USD","LU1804176565.USD","LU1868836757.USD","IE00BZ1G4Q59.USD","LU2237443465.HKD","LU2347655156.SGD","BK4588","BK4581","LU1548497426.USD","LU0251142724.SGD","LU2237443895.HKD","LU2265009873.SGD","IE0034235188.USD","LU1791710582.SGD","IE0004086264.USD","LU2750360641.GBP","LU1244550577.SGD","LU0267386448.USD","LU2271345857.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614889265","title":"AI製藥企業Generate Biomedicines(GENB.US)IPO定價16美元/股 今晚登陸納斯達克","url":"https://stock-news.laohu8.com/highlight/detail?id=2614889265","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614889265?lang=zh_tw&edition=fundamental","pubTime":"2026-02-27 14:50","pubTimestamp":1772175025,"startTime":"0","endTime":"0","summary":"专注于免疫学与肿瘤学领域的AI药物研发公司Generate Biomedicines(GENB.US)正式公布美股IPO发行价。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260227/20260227145043_27698.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260227/20260227145043_27698.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"AI制药企业Generate Biomedicines(GENB.US)IPO定价16美元/股 今晚登陆纳斯达克","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["GENB","BK1191","BK1147","BK1574","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}